Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Nkarta, Inc. (NKTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 • Cash and cash equivalents of $332.1 million on March 31, 2023 • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, today reported financial results for the first quarter ended March 31, 2023. “Nkarta remains focused on the potential of donor-derived CAR NK cell products to broaden access to the transformative power of cell therapy for patients,” said Paul J. Hastings, CEO and President of Nkarta. &#x..." |
|
| 03/16/2023 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/17/2022 |
8-K
| Quarterly results|
Docs:
|
"Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights • On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022 – 1H 2022 - NKX101, a CAR NK cell therapy candidate engineered with NKG2D receptor, in relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome – FY 2022 - NKX019, a CAR NK cell therapy candidate engineered with CD19 receptor, in relapsed/refractory B cell malignancies SOUTH SAN FRANCISCO, Calif., March 17, 2022 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2021. “2021 was a year of solid execution for ..." |
|
| 11/10/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 05/13/2021 |
8-K
| Quarterly results |
| 03/25/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results|
Docs:
|
"Cash and Cash Equivalents: As of September 30, 2020, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $330.2 million, which includes proceeds from the Company’s July 2020 IPO of $265.1 million, net of underwriting discounts and commissions and other offering costs. • R&D Expenses: Research & development expenses were $9.8 million for the third quarter of 2020, which includes $0.7 million of non-cash stock-based compensation expense. • G&A Expenses: General and administrative expenses were $3.9 million for the third quarter of 2020, which includes $0.9 million of non-cash stock-based compensation expense. • Net Loss. Net loss was $13.7 million, or $0.44 per basic and diluted share, for the quarter ended September 30, 2020. Financial Guida...",
"Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D‑Based NK Cell Cancer Immunotherapy NKX101" |
|
| 08/20/2020 |
8-K
| Quarterly results |
|
|